Abstract:Immune thrombotic thrombocytopenic purpura (iTTP) is a life-threatening disease. iTTP develops due to autoantibodies to the ADAMTS-13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) enzyme. These antibodies lead to functional deficiency of ADAMTS-13, which results in the circulation of ultra-large von Willebrand factor (VWF) multimers and leads to thrombocytopenia, hemolysis, and organ ischemia.[1] ADAMTS-13 autoantibodies can be triggered by certain antiplatelet drugs, immunosuppressive agents, human immunodeficiency virus (HIV), estrogen-containing contraceptives, and pregnancy. Initial iTTP treatment may include plasma exchange (PEX)[2] and immunosuppressive therapy (glucocorticoids and rituximab).[3] Such treatment increased the survival rate of patients with iTTP to 78%.[4] The introduction of caplacizumab has dramatically improved the results of iTTP treatment. Caplacizumab forms a part of so-called triplet therapy, which includes daily PEX from the first day until the platelet count is ≥150 × 10 9 /L, administration of immunosuppression (prednisolone 1 mg/kg and rituximab at a dose of 375 mg/m 2 intravenously on days 1, 4, 8 and 15) and caplacizumab. Caplacizumab is recommended for 30 days after cessation of PEX.[5] However, some patients may achieve remission earlier than the 30-day period, while others may require more than 30 days to reach an ADAMTS-13 activity level of ≥20%. Between February 2021 and March 2024, 24 patients were diagnosed with iTTP based on clinical manifestations, thrombocytopenia, hemolytic anemia, ADAMTS-13 activity level of less than 10%, and presence of the ADAMTS-13 inhibitor ([Table 1]). Data presented as median and range (difference between lowest and highest values). Characteristic Value Age, y, median (range) 43 (18–68) Female, n 18 (75%) De novo iTTP, n 20 (83%) iTTP relapse, n 4 (17%) Clinical presentations Neurological/mental disorders, n 15 (63%) Thrombocytopenia, n 24 (100%) Hemorrhagic syndrome, n 24 (100%) Anemia, n 24 (100%) ADAMTS-13 activity, %, median (range) 0 (0–3.1) ADAMTS-13 inhibitor, BU, median (range) 2.5 (0.4–14.0) Platelet count, ×10 9 /L, median (range) 18 (1–59) Hemoglobin, g/L, median (range) 81 (48–111) Schistocyte count, % median (range) 1 (0–13) LDH, U/L, median (range) 564 (281–3,025) PEX from suspicion of TTP to triplet therapy Number of patients, n 7/24 Number of PEX, median (range) 4 (1–8) Total volume, mL, median (range) 8,000 (2,000–16,000) Abbreviations: ADAMTS-13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; iTTP, immune thrombotic thrombocytopenic purpura; LDH, lactate dehydrogenase; PEX, plasma exchange; TTP, thrombotic thrombocytopenic purpura. After clinical suspicion of iTTP, prior to receiving the ADAMTS-13 activity results, 7 of 24 patients immediately underwent PEX procedures; however, these patients continued to exhibit thrombocytopenia, anemia, and clinical signs of iTTP before the start of the triplet therapy. We therefore modified the triplet therapy and tailored it based on the ADAMTS-13 activity. The modification of the triplet therapy included the time of initiation of treatment with rituximab and duration of therapy with caplacizumab and rituximab. After confirming the diagnosis of iTTP with ADAMTS-13/inhibitor testing, we initiated or continued treatment with daily PEX and started prednisolone (1 mg/kg/d) and caplacizumab. Patients received an intravenous loading dose of caplacizumab (10 mg) before the start of the first PEX. Subsequent doses (10 mg) were administered subcutaneously, once daily. Caplacizumab was provided free of charge via Sanofi's Managed Access Program. Sanofi was not involved in the design, collection, analysis, interpretation, or reporting of data, but was given the opportunity to review the publication prior to submission. The decision to submit for publication was made independently by the authors. We continued PEX until the platelet count increased to ≥150 × 10 9 /L, then we stopped PEX, but continued caplacizumab and prednisolone. Only after stopping PEX did we start rituximab (375 mg/m 2 intravenously once a weekly; [Fig. 1]). Caplacizumab was stopped only after the ADAMTS-13 activity reached ≥20% (partial ADAMTS-13 remission). Rituximab and prednisolone were continued until the ADAMTS-13 activity reached ≥40% (complete ADAMTS-13 remission), then rituximab was stopped and the dose of prednisolone was gradually tapered off. In the week after the triplet therapy, neurological and cognitive disorders had regressed in all previously affected patients. The median time from the start of t -Abstract Truncated-

Successful use of a second course of caplacizumab in relapsed thrombotic thrombocytopenic purpura

Caplacizumab for Acute Thrombotic Thrombocytopenic Purpura

Caplacizumab improves clinical outcomes and is well tolerated across clinically relevant subgroups of patients with immune-mediated thrombotic thrombocytopenic purpura

Caplacizumab as an add-on therapy in a 7-year-old girl with exacerbated immune-mediated thrombotic thrombocytopenic purpura, a case report and literature review

Successful Treatment of Acquired Thrombotic Thrombocytopenic Purpura With Caplacizumab Combined With Plasma Exchanges and Immune Suppression in 3 Children

Management of Immune Thrombotic Thrombocytopenic Purpura without Therapeutic Plasma Exchange: Analysis of Efficacy and Safety Data

The Roscapli Study

Five years of caplacizumab - lessons learned and remaining controversies in immune-mediated thrombotic thrombocytopenic purpura

Management of Immune Thrombotic Thrombocytopenic Purpura without Therapeutic Plasma Exchange

Outcomes in 1096 patients with severe thrombotic thrombocytopenic purpura before the Caplacizumab era

Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura

Caplacizumab in paediatric immune thrombotic thrombocytopenic purpura (iTTP): the UK TTP Registry experience.

Should we consider caplacizumab as routine treatment for acute thrombotic thrombocytopenic purpura? An expert perspective on the pros and cons

Outcomes and Costs in Patients with Immune Thrombotic Thrombocytopenic Purpura Receiving Front-Line Versus Delayed Caplacizumab: A US Hospital Database Study

Long-term remission induced by low-dose rituximab for relapsed and refractory thrombotic thrombocytopenic purpura: A report of two cases.

Safety and efficacy of caplacizumab in a case of thrombotic thrombocytopenic purpura in the postpartum period

Refining the standard of care in immune thrombotic thrombocytopenic purpura

Tailored Treatment of Immune Thrombotic Thrombocytopenic Purpura

Successful Treatment of Plasma Exchange-Refractory Thrombotic Thrombocytopenic Purpura with Rituximab: A Case Report

Adamts13 Recovery In Acute Thrombotic Thrombocytopenic Purpura After Caplacizumab Therapy. The Spanish Registry

Persistent ADAMTS13 Inhibitor Delays Recovery of ADAMTS13 Activity in Caplacizumab-Treated Japanese iTTP Patients